MELANOCORTIN SYSTEM & AROUSAL / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to these two melanocortin research peptides.
What is PT-141?
PT-141 is a common research name for bremelanotide, a synthetic cyclic heptapeptide that activates melanocortin 4 receptor (MC4R) in the brain. Under its pharmaceutical name bremelanotide, it received FDA approval in 2019 as an as-needed treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [5]. In research-use contexts outside that approved indication, it is referred to as PT-141. The compound's mechanism is central: it acts on brain circuits that generate sexual desire, not on blood vessels [7].
What is PT-141 peptide?
PT-141 is a peptide — a short chain of amino acids — specifically a cyclic (ring-shaped) seven-amino-acid structure derived from the natural brain hormone alpha-melanocyte-stimulating hormone (alpha-MSH). The ring is formed by a lactam bridge between two of the amino acids, giving it stability against enzyme breakdown. It is structurally related to Melanotan 2 but differs in the chemical group at the end of the peptide chain, which contributes to its greater MC4R selectivity over other melanocortin receptor subtypes [11].
What does the PT-141 peptide do?
PT-141 activates melanocortin 4 receptor (MC4R) in the hypothalamus and limbic brain regions, engaging the neural circuitry of sexual desire and arousal — not blood vessels. In the pivotal Phase 3 trials (n=1,267 premenopausal women with HSDD), it produced statistically significant improvements in sexual desire and reductions in desire-related distress over 24 weeks [3]. A neuroimaging study in 31 women with HSDD showed it also alters how the brain processes erotic stimuli, increasing amygdala-insula connectivity [2]. In rats and nonhuman primates, it activated hypothalamic neurons and produced dose-dependent erectile activity [7].
What is PT-141 used for?
In its approved form (bremelanotide), PT-141 is used for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — specifically low sexual desire that causes significant personal distress [5]. This is the only approved indication. Off-label research has examined its effects in men with erectile dysfunction and in other populations, but those uses lack approved status and the evidence is more limited than the HSDD trials. 'PT-141 research chemical' sold outside pharmacy channels is for laboratory research use only, not for human consumption in the approved-use sense [5].
What is Melanotan 2?
Melanotan 2 is a synthetic cyclic heptapeptide derived from alpha-MSH, developed at the University of Arizona in the late 1980s to be a superpotent, enzyme-resistant melanocortin agonist [11]. Unlike PT-141, it is non-selective: it activates all five melanocortin receptor subtypes (MC1R through MC5R). MC1R activation drives skin pigmentation; MC4R activation drives sexual arousal; MC3R activation reduces appetite. Melanotan 2 has never been approved for any use by any major regulator, and no Phase 2 or Phase 3 clinical trial has been completed for any indication.
What is Melanotan 2 used for in research?
Research on Melanotan 2 has centered on three areas: skin pigmentation (tanning via MC1R), male erectile function (the 1998 controlled study produced erections in 8 of 10 men with psychogenic erectile dysfunction [12]), and appetite/energy balance (mesolimbic MC3R/MC4R signaling reduced food motivation in mice without metabolic-rate change [9]). It was also the precursor compound in the drug-development program that led to PT-141 (bremelanotide), which was engineered to be more selective and better tolerated [11]. Melanotan 2 itself did not proceed to late-phase trials.
How does Melanotan 2 work in the body?
Melanotan 2 activates melanocortin receptors MC1R through MC5R simultaneously. On skin melanocytes, MC1R activation raises intracellular cAMP and drives the PKA-CREB-MITF cascade that upregulates tyrosinase, shifting pigment synthesis toward dark eumelanin — producing skin darkening without requiring UV. In the hypothalamus and limbic brain, MC4R activation engages sexual-motivation circuitry, producing arousal and erection. In mesolimbic circuits, MC3R/MC4R signaling reduces appetite and food motivation [9][11]. This simultaneous multi-receptor activity is both the source of its broad effects and the origin of its broader adverse-event profile compared to the more selective PT-141.
What is the melanogenesis (MC1R-cAMP-MITF) signaling cascade?
Melanogenesis is the process by which skin cells called melanocytes produce the pigment melanin. The MC1R-cAMP-MITF cascade describes the molecular steps: Melanotan 2 binds to MC1R on the melanocyte surface → MC1R activates adenylyl cyclase → intracellular cAMP rises → protein kinase A (PKA) is activated → PKA activates CREB (cAMP response element-binding protein) → CREB upregulates the transcription factor MITF (Microphthalmia-Associated Transcription Factor) → MITF drives transcription of tyrosinase and related enzymes → tyrosinase converts tyrosine to melanin, specifically eumelanin (dark) rather than pheomelanin (red/yellow) [11]. This cascade is also what darkens moles and produces the oral mucosal pigmentation documented in case reports [8].
Is PT-141 the same as Melanotan 2?
No. They are related but distinct compounds. Both are cyclic heptapeptides derived from alpha-MSH and both activate melanocortin receptors, but PT-141 (bremelanotide) has a carboxylic acid at its C-terminus while Melanotan 2 has an amide. This chemical difference contributes to PT-141's greater selectivity for MC4R over MC1R, which is why PT-141 produces arousal with less pigmentation, while Melanotan 2 produces both strongly. They also have entirely different regulatory histories: PT-141 is FDA-approved for HSDD in premenopausal women; Melanotan 2 is not approved for anything anywhere [5][11].
Does PT-141 work for men?
PT-141 is not FDA-approved for any use in men. Early research demonstrated dose-dependent erectile activity in men with erectile dysfunction in animal and initial human studies [7], and community reports in the off-label male research-use context frequently describe spontaneous erections and increased sexual interest. However, this use is off-label, lacks the controlled-trial evidence base that exists for the approved HSDD indication, and carries the same cardiovascular and other cautions as the approved use. This site makes no recommendation regarding off-label use.
What are the main side effects of PT-141?
In the Phase 3 trials and long-term extension (n up to 684 women), the most common treatment-emergent adverse events were nausea (40.4% over 52 weeks), flushing (20.6%), and headache (12.0%) [4]. A transient blood-pressure rise and a corresponding small drop in heart rate are documented effects; the label explicitly warns against use in people with uncontrolled hypertension or cardiovascular disease [5]. With overly frequent dosing, hyperpigmentation of the face, gums, and breasts can occur due to off-target MC1R activation. Individual reports in research-use communities also mention fatigue, drowsiness, injection-site reactions, and — in a real subset — no benefit at all.
What are the risks of Melanotan 2?
Melanotan 2 carries a documented serious adverse-event record from case reports, including: renal infarction with proposed thrombotic mechanism [10], rhabdomyolysis and acute kidney injury, priapism (prolonged painful erection that can cause permanent damage), posterior reversible encephalopathy syndrome (PRES), oral mucosal pigmentation [8], eruptive new nevi and dysplastic (atypical) nevi, and melanoma in users [11]. Nausea, flushing, and the distinctive yawning/stretching reflex are very commonly reported. Any new or changing mole during or after use warrants prompt dermatological assessment. Unregulated Melanotan 2 products are repeatedly found to be mislabeled and impure, compounding these risks [11].
What does 'HSDD' mean, and why is it the approved indication?
HSDD stands for hypoactive sexual desire disorder — specifically, persistently low or absent sexual desire that causes significant personal distress and is not explained by a relationship issue or another medical condition. The 'acquired, generalized' form (the approved indication) means the low desire developed after a period of normal desire and occurs across situations, not only with a specific partner. PT-141 is approved for this indication in premenopausal women specifically because that is who the Phase 3 trials enrolled [3][5]. Postmenopausal women and men were not included in those pivotal studies, so the approval does not extend to them.